x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012417
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro413 of human PFAS protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PFAS |
| UniProt No. | O15067 |
| Gene ID | 5198 |
| Gene Description | Phosphoribosylformylglycinamidine synthase is a metabolic enzyme associated with a protein complex known as the “purinosome, ” which is involved in de novo purine synthesis. Research studies have shown that activation of the MAPK/ERK pathway leads to downstream activation of PFAS. Specifically, it was shown that PFAS is a substrate of ERK2, which phosphorylates PFAS at Thr619; activation of PFAS results in the de novo generation of purine intermediates required for cell and tumor growth. It has also been reported that both PFAS and viral PFAS-like proteins can activate RIG-I pattern recognition receptors, implicating PFAS-mediated deamidation in the innate immune response to viral infection. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
